

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Original) A stabilized pharmaceutical solid composition comprising of an ACE inhibitor and meglumine.
2. (Original) A stabilized composition of claim 1, where in the ACE inhibitor is selected from the group of enalapril, delapril, lisinopril, moxipril, perindopril, ramipril,trandolapril and pharmaceutically acceptable salts thereof.
3. (Original) A stabilized composition of claim 2, wherein the ACE-inhibitor is ramipril.
4. (Original) A stabilized composition of claim 3, wherein the amount of ramipril in the composition is from about 1 mg to about 10 mg.
5. (Original) A stabilized composition of claim 1, wherein the ratio of ACE-inhibitor to meglumine is from about 1:0.01 to about 1:2.0.
6. (Original) A stabilized composition of claim 5, wherein the ratio of ACE-inhibitor to meglumine is preferably from about 1:0.03 to about 1:1.2.
7. (Original) A stabilized composition of claim 1, which further comprises of a diluent.
8. (Original) A stabilized composition of claim 7, wherein the diluent is selected from amongst low substituted hydroxypropyl cellulose and pregelatinized starch.
9. (Original) A stabilized composition of claim 7, wherein the ratio of ACE-inhibitor to diluent is from about 1:10 to about 1:100.
10. (Original) A stabilized composition of claim 1 wherein the dosage formulation further comprises of lubricant.

11. (Original) A stabilized composition of claim 10, wherein the lubricant is a stearate, which is selected from the group consisting of magnesium stearate, zinc stearate and calcium stearate.
12. (Original) A stabilized composition of claim 10, wherein the lubricant is magnesium stearate.
13. (Original) A stabilized composition of claim 10, wherein the amount of lubricant in the composition is from about 0.2 mg to about 2 mg.
14. (Original) A stabilized composition of claim 10, wherein the amount of lubricant in the composition is from about 0.5 mg to about 1.5 mg.
15. (Original) A stabilized pharmaceutical ACE inhibitor composition comprising ramipril and meglumine along with at least one of low substituted hydroxypropyl cellulose, pregelatinized starch and magnesium stearate.
16. (Original) A stabilized composition of claim 1 in any dosage form.
17. (Original) A stabilized composition of claim 16 wherein the composition is filled into a capsule.
18. (Original) A stabilized composition of claim 16 wherein the composition is made into a tablet.
19. (Original) A process of preparation of a stable formulation of ACE-inhibitor comprising mixing of the ACE inhibitor with meglumine and optionally at least one of a diluent and a lubricant followed by compressing the mixture to a tablet or filling the mixture into a capsule.
20. (Original) The process as claimed in Claim 19 wherein the diluent is selected from amongst low substituted hydroxypropyl cellulose and pregelatinized starch.
21. (Original) The process as claimed in Claim 19 wherein the lubricant, is selected from the group consisting of magnesium stearate, zinc stearate and calcium stearate.
22. (Original) The process as claimed in Claim 21 wherein the lubricant is magnesium stearate.
23. (Cancelled)